MRNS Marinus Pharmaceuticals, Inc.

1.17
+0.00  (0%)
Previous Close 1.17
Open 1.17
Price To book 1.33
Market Cap 26.23M
Shares 22,419,000
Volume 141,647
Short Ratio 2.72
Av. Daily Volume 469,992

SEC filingsSee all SEC filings

  1. 8-K - Current report 17844157
  2. 8-K - Current report 17805207
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17801807
  4. CT ORDER - Confidential treatment order 17761295
  5. 8-K - Current report 17758065

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due mid-2017.
Ganaxolone
CDKL5 disorder